6 days Ago By ABMN Staff
Russell Investments Group Ltd. trimmed its stake in shares of Omnicell, Inc. ( NASDAQ:OMCL – Free Report ) by 6.
8% in the fourth quarter, Holdings Channel.com reports. The fund owned 105,097 shares of the company’s stock after selling 7,643 shares during the period.
Russell Investments Group Ltd.’s holdings in Omnicell were worth $4,679,000 at the end of the most recent reporting period. Several other institutional investors have also modified their holdings of the company.
Geode Capital Management LLC grew its holdings in Omnicell by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares during the last quarter.
Franklin Resources Inc. grew its stake in Omnicell by 49.9% in the 3rd quarter.
Franklin Resources Inc. now owns 30,807 shares of the company’s stock valued at $1,316,000 after acquiring an additional 10,260 shares during the last quarter. Nordea Investment Management AB increased its holdings in Omnicell by 4.
3% during the 4th quarter. Nordea Investment Management AB now owns 121,722 shares of the company’s stock valued at $5,372,000 after acquiring an additional 5,068 shares in the last quarter. Accurate Wealth Management LLC raised its position in Omnicell by 33.
4% during the fourth quarter. Accurate Wealth Management LLC now owns 28,369 shares of the company’s stock worth $1,199,000 after acquiring an additional 7,109 shares during the last quarter. Finally, Arkadios Wealth Advisors raised its position in Omnicell by 27.
6% during the fourth quarter. Arkadios Wealth Advisors now owns 43,454 shares of the company’s stock worth $1,935,000 after acquiring an additional 9,404 shares during the last quarter. Hedge funds and other institutional investors own 97.
70% of the company’s stock. Wall Street Analyst Weigh In A number of brokerages have recently weighed in on OMCL. Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.
00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Bank of America cut their price target on Omnicell from $54.
00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co.
decreased their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th.
StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Finally, Benchmark reissued a “buy” rating and set a $62.
00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus price target of $51.
00. Omnicell Stock Performance NASDAQ OMCL opened at $31.61 on Tuesday.
The business’s 50-day simple moving average is $36.08 and its 200-day simple moving average is $41.59.
The firm has a market capitalization of $1.48 billion, a P/E ratio of 117.08, a P/E/G ratio of 7.
53 and a beta of 0.78. Omnicell, Inc.
has a 1-year low of $25.12 and a 1-year high of $55.75.
The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.
22. Omnicell ( NASDAQ:OMCL – Get Free Report ) last issued its earnings results on Thursday, February 6th. The company reported $0.
45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12).
Omnicell had a net margin of 1.13% and a return on equity of 3.82%.
Equities analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.
Omnicell Company Profile ( Free Report ) Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. See Also Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Omnicell, Inc. ( NASDAQ:OMCL – Free Report ). Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.
com's FREE daily email newsletter ..
